The A 69-year-old woman was referred for further evaluation and management of relapsed angioimmunoblastic T-cell lymphoma.Atdiagnosis,shereceivedsixcyclesofdose-adjustedEPOCH(etoposide,prednisone,vincristine,cyclophosphamide, and doxorubicin) and achieved a complete response (CR). Her first surveillance computed tomography scan 3 months later demonstrated enlarging cervical lymphadenopathy. A lymph node excision confirmed relapsed angioimmunoblasticT-celllymphomawithatypicallymphocytesexpressingCD3,CD4,CD10,PD-1,andEBER,withlossof CD5(Fig1).AclonalT-cellreceptorbetaandgammarearrangementbypolymerasechainreactionwasidenticaltothat in her initial diagnostic biopsy. At our initial consultation, options for standard as well as investigational therapies were discussed, and HLA typing was initiated. The patient was enrolled onto an investigational phase II study; however, she developed progressive disease after two cycles. She was then treated with romidepsin 14 mg/m 2 administered intravenouslyfor3consecutiveweekswith1weekoff.Aftertwocycles,sheachievedapartialresponse,andafterfouradditional cycles, she maintained her response without further improvement. We discussed additional treatment options.
been studied by the German High-Grade Non-Hodgkin Lymphoma Study Group and most recently by the Nordic Lymphoma Group as part of a first-line autologous strategy. 8, 9 In the Nordic study, CHOEP had an ORR of 82%, with 51% attaining a CR and 70% responding adequately enough to move forward to consolidative stem-cell transplantation. Multiple alternative regimens to CHOP have been studied, but none are clearly superior. 7, [10] [11] [12] [13] Consolidative transplantation strategies remain an appealing option in first remission. 5, 9, [14] [15] [16] For those with primary refractory or relapsed PTCL, the optimal approach to management is unclear, and data regarding the outcome for these patients is limited. A common paradigm is to treat with second-line combination regimens similar to those studied in relapsed aggressive B-cell lymphomas. Although earlier studies of these regimens, such as ICE (ifosphamide, carboplatin, and etoposide), DHAP (dexamethasone, cytarabine, and cisplatin), and ESHAP (etoposide, methylprednisolone, cisplatin, and cytarabine), included patients with T-cell lymphoma, the T-cell lymphoma subsets have never been identified or retrospectively analyzed. [17] [18] [19] [20] 
SUMMARY OF THE RELEVANT LITERATURE
In the report accompanying this article, Mak et al 21 present the outcomes for patients with relapsed and refractory PTCL-NOS, AITL,
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and ALCL treated at the British Columbia Cancer Agency (BCCA) from 1976 to 2010. This represents the largest reported series of relapsed and refractory disease for the most common subtypes of PTCL. This study excluded those who proceeded to hematopoietic stem-cell transplantation, and the study found few long-term survivors. Of the 153 patients in the series, the median OS was 5.5 months. For the subset of patients in this series who received treatment, the median OS was only marginally longer at 6.5 months. The treatment strategies reported are typical of those used for relapsed lymphoma, with 91 patients (58%) receiving chemotherapy, including 46% as part of a multidrug regimen.
Until recently, our understanding of the prognosis for patients was gleaned from small phase II clinical trials where the reports are focused on response rates with little information on OS (Table 1) . 22-26a Large phase II studies have now been completed, providing valuable information regarding the prognosis for this patient population. The phase II studies for romidepsin and pralatrexate enrolled 130 and 111 patients, respectively, and led to the approval of these drugs in relapsed and refractory PTCLs.
27-28a Interestingly, we see apparent differences in outcomes in these large phase II studies compared with the BCCA series. In the two studies, the ORR was 29% for pralatrexate and 25% for romidepsin, with median OS of 14.5 and 11.3 months, respectively. These survival figures are double that seen in the BCCA series, and it seems that the tails of those curves show more patients alive beyond 2 and 3 years. It can be perilous to draw conclusions by comparing phase II clinical trial results with population-based registry outcomes. However, in a disease where we lack randomized studies, such are the data we have to help guide decisions. What could account for the different outcomes? Patient selection is one likely contribution. Patients in trials tend to be in better shape. Most had Eastern Cooperative Oncology Group performance status (PS) of 0 to 1, whereas PS was Ն 2 in 50% of the historical controls. In addition to PS, the populations differed by prior therapy. The BCCA patients were described from first relapse, whereas those in the prospective studies were enrolled after a median of 2 to 3 prior therapies. The patients in the clinical trials were further along in their disease courses (Ͼ 15 months from diagnosis in both pralatrexate and romidepsin studies v 6.6 months from diagnosis in the BCCA series) but still showed longer survival. Another possibility is that the new drugs are actually more effective. They are certainly better studied, but a conclusion that they are more active is hard to support when their ORRs were approximately 25% to 30%, and the ORR for all therapies reported by Mak et al 21 was 55%.
A A third distinction might be the difference between short-course combination versus continuous therapy. We know that remissions while not receiving therapy are often short in PTCLs, even in the first-line setting. In the studies of the new agents, because of study design and lack of cumulative toxicity, patients were able to be treated until progression or intolerance so that responding patients maintained their remissions. We see the potential benefits of this approach in the median durations of response: pralatrexate, 10.1 months; romidepsin, 28 months; and brentuximab vedotin, 13 months (ALCL only). 29 In these trials, excluding that involving brentuximab vedotin, where therapy was capped at 1 year, patients who did not experience progression could continue therapy, and they may have had their disease control extended by this approach. Combination chemotherapy with non-cross-reactive regimens DHAP, ICE, ESHAP, Gem-P (gemcitabine, cisplatin, and methylprednisolone), and GCD (gemcitabine, cisplatin, and dexamethasone) has traditionally been used. [18] [19] [20] 30, 31 However, there are few published data for these regimens in PTCL. Combination chemotherapy regimens may result in higher response rates, but because of cumulative toxicity, they are usually only administered for three to four cycles. This may work well as a bridge to stem-cell transplantation, but it lacks durability as a standalone option. For example, in our experience with ICE as second-line therapy, we found an ORR of 70% among the 40 patients we treated; however, despite two thirds of these patients preceding to autologous stem-cell transplantation (ASCT), our median progressionfree survival was Ͻ 6 months. 32 In a study of Gem-P for relapsed PTCL, an ORR of 69% was seen in 16 patients; however, the time to progression was only 4 months. 30 A recent example of the potential benefits of continuous versus interrupted therapy for relapsed PTCL comes from a trial of bendamustine. 33 In that study, 60 patients with relapsed PTCL were treated with bendamustine, with an ORR of 50%. Despite the higher response rate as compared with pralatrexate and romidepsin, the median duration of response was only 3.5 months, and the median OS was 6.2 months. Most patients received Ͻ four cycles of therapy.
It is important to note that the use of transplantation in our more-current treatment paradigms may be holding up the tails of the curves. Our institutional data and others have shown that the use of ASCT for relapsed PTCL, with a possible exception of ALCL, has rarely resulted in long-term disease control. 32, 34 This is somewhat controversial, and some registry data point to better results with ASCT at relapse, although these series are overrepresented by ALCL.
35 Meanwhile, the emerging experience with allogeneic transplantation looks promising. Both myeloablative and reduced-intensity allogeneic stem-cell transplantation have demonstrated up to 60% 3-year progression-free survival. [36] [37] [38] In the BCCA series, only 29% of patients at relapse were felt to be transplantation eligible. However, this series spans more than three decades, and in the current era of reduced-intensity transplantation, the definition of transplantation eligible is surely much broader. As more patients who respond to therapy at relapse are cured with allogeneic stem-cell transplantation, the tails of the curves are sure to be extended.
Clinical trials remain an integral part of the care of patients with relapsed PTCL. Agents in development are initially studied in the relapse setting and most often follow the paradigm set forth by pralatrexate and romidepsin of disease control and maintenance of a response. Currently, there are several single agents in development for relapsed PTCL, and until highly effective therapies are developed, participation in a clinical trial should be strongly considered whenever a new line of therapy is needed (Table 2) .
SUGGESTED APPROACHES TO MANAGEMENT
Without comparative data, our practice patterns are informed by the available literature and our personal experience. For the purposes of creating an algorithmic approach, our general assumptions are that in the relapsed setting, allogeneic transplantation is the only reliably curative approach, and outside of a curative approach, the best chance at achieving a durable remission is through a continuous treatment approach. On the basis of these assumptions, patients with relapsed disease can be subdivided into three basic groups with regard to their potential for curative therapy: transplantation soon, transplantation never, or transplantation unclear, with the majority falling into this last category (Fig 2) .
Transplantation Soon
Candidates for early transplantation include those without significant comorbidities and with a known donor identified and available. The treatment goal is to achieve a quick remission and then consolidation with allogeneic stem-cell transplantation. The situations where autologous transplantation may be considered curative, such as relapsed ALK-positive ALCL, could be included here. We believe combination chemotherapy with common second-line regimens such as ICE (our preferred choice if relapse is after CHOP), ESHAP, or DHAP or others offers the highest chance of inducing both prompt and often complete remission. This allows the patient to proceed to transplantation after two to three cycles of second-line therapy. Because patients with PTCL have a propensity to relapse quickly when not receiving therapy, we try to avoid delays between second-line therapy and the conditioning regimen and consequently reserve this initial approach for those who already have an identified donor. Even in these cases, organizing the transplantation plan must be expedited. If, for example, three cycles of ICE are administered every 17 to 21 days, this means that a patient should be ready to be admitted for transplantation Ͻ 10 weeks from day 1 of his or her first ICE treatment.
Transplantation Never
We categorize here patients whose comorbidities or personal choices eliminate curative therapy as an option. Historically, age (with definitions changing over time) and lack of an HLA-matched donor could also be reasons to include someone in this category. However, the increasing use of reduced-intensity transplantation and alternate stem-cell sources make this group more challenging to define. We frequently consult with our transplantation service before assigning individuals to this group. Without transplantation, the therapeutic goal is to maintain remission. We treat with single agents and welltolerated combinations, with the goal of achieving disease control and maintaining as good a quality of life as possible for as long as possible while administering therapy. Currently, outside of brentuximab vedotin for relapsed ALCL, the data for the available single agents are insufficient to endorse one over another as first choice in this setting. Rather, schedule and administration, potential adverse effects, previous therapy, and physician comfort in addition to patient preferences often guide the choice, because all these agents have response rates Ͻ 50%. Choice of therapy at relapse becomes less about picking the best agent to use and more about organizing potential treatments in order of which to try first, second, third, and so on. By using this sequential approach and capitalizing on our increasing number of active therapies for PTCL, a significant subset of patients can have their disease controlled to surpass the median survival times described in the series by the BCCA. This is also an opportune place to incorporate clinical trials, because there are a number of novel drugs in development, including oral agents and antibodies, that fit this paradigm.
Transplantation Unclear
In the transplantation-unclear group, which in our experience is the largest subset, comprising approximately two thirds of our relapsed PTCL population, we use a hybrid of the two approaches described. At time of relapse for a patient who is a potential transplantation candidate, we initiate HLA typing and a transplantation consultation concurrently with planning therapy. In these cases, we generally start therapy with one of the single agents or mild combinations therapies that can be continued. We have a strong bias toward investigational therapies in this setting. If a response is achieved, and a transplantation plan is made, patients can transition directly to transplantation, as we have seen in the phase II studies of pralatrexate, romidepsin, and brentuximab vedotin. If a response is achieved, and a transplantation option does not materialize, the patient needs time to consider his or her preferences, or, as is often the case with matched unrelated donors, it takes some time to organize transplantation, the patient can continue to receive therapy until things are in place. This approach avoids the quickly ticking clock associated with the moreaggressive second-line regimens that carry a higher risk of cumulative toxicity after several cycles. If a response to the investigational agent or single agent is not seen, and a transplantation plan is set, the patient can then be transitioned to one of the combination regimens to try to induce a prompt remission and move to transplantation. If a response is not seen, and no transplantation plan is in place, we generally offer an alternate single agent or alternate investigational agent.
Mak et al 21 provide valuable information regarding the prognosis for patients with relapsed PTCL. With newer agents now available, such as romidepsin, pralatrexate, and brentuximab vedotin, and others in development, a greater proportion of relapsed patients will have longer disease control, raising and extending the tails of these survival curves. Ultimately, more-effective first-line regimens will make discussions about the tails of the curves unnecessary. However, until that time, strategies that integrate clinical trials, sequential treatment with less toxic, better-tolerated agents, and selective use of allogeneic stemcell transplantation seem to be the best ways we have of extending survival.
After much discussion, our patient elected to proceed to reducedintensity matched unrelated donor stem-cell transplantation. She obtained a complete remission at her first post-transplantation evaluation. She is currently 2 years post-transplantation without evidence of disease, with grade 2 chronic graft-versus-host disease of the skin. Recommended approach to patients with relapsed peripheral T-cell lymphomas (PTCLs) regarding additional therapies and goals of care. AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic largecell lymphoma; ICE, ifosphamide, carboplatin, and etoposide; NOS, not otherwise specified; POD, progression of disease.
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